Document resource
Introduction Systemic Sclerosis (SSc) is a rare autoimmune systemic disease which had a negative impact in health outcomes, however there is not data in Latin American region currently, specialty in patients’ perspective.Material and Methods A cross-sectional analysis from the first single center Ssc Peruvian cohort (Hospital Almenara EsSalud). The cohort includes patients with SSc who accomplish the ACR-EULAR 2013 criteria, with at least 16 years and who signed an informed consent. Exclusion criteria are overlapping syndromes with other autoimmune diseases, current infection, and pregnancy. The cohort started in November 2023, and patients are evaluated biannually. Clinical examination, medical records reviews. laboratory test and images including thorax CTA are performed on each visit. Variables analyzed were sociodemographic (age, gender, socioeconomic level, and education), disease features (disease duration, diagnosis delay, an clinical features), autoantibodies, laboratory test, treatment : c-DMARDs and b-ts DMARDs and patient reported outcomes which explored quality of life (Systemic Sclerosis Questionnaire: SySQ), disability (Multidimensional Health Assessment Questionnaire: MD-HAQ), fatigue (Functional Assessment of Chronic Illness Therapy- Fatigue: FACIT-F ), hand disability (Cochin questionnaire), and depression (Patient Health Questionnaire-9: PHQ-9 questionnaire). We used descriptive statistics to summarize the data (means, standard deviations, medians and interquartile ranges, as well as frequency distributions).Results Seventy-four patients were evaluated; 63 (85%) were female, the age was 56 (17) years, disease duration 10 (4-14) and diagnosis delay 2.0 (1-5) years. The modified Rodnan score (mRss) was 7(4-14) and the most frequent subtype was limited cutaneous SSc [39(52%)], ILD was present in 52 (70.27%) patients, dyspnea in 35 (47%), Raynaud in 32 (43%), Pulmonary Arterial Hypertension (HAP) in 8 (11%) and Tendon Friction Rubs in 2(3%) patients. The most prevalent antibody were anti-topoisomerase (Scl70) [31(45%)] and anti-Ro-52 [14(19%)]. The ESR and CRP were 28 (19-46) mm/h and 5 (3-7) mg/L respectively. SySQol was 0.7 (0.4-1.1), Cochin questionnaire: 6 (0-21), MDHAQ: 0.6 (0.3-1.1) and PHQ-9 :5 (3-11); c-DMARDs was used in 64 (86%) patients being mycophenolate mofetil the most prescribed in 54 (73%); only 8 (11%) of patients received b-tsDMARDs.Conclusions As for previous reports, our cohort has a female predominance, with higher delay of diagnosis. Limited cutaneous subset and anti-topoisomerase were the clinical presentation and autoantibodies most frequently. ILD had a higher prevalence. Mycophenolate mofetil was the most used drug. We could identify thought PROMs impact in QoL, functional, hand disability and emotional dimension of our patients.Abstract P.290 Table 1Sociodemographic, clinical and laboratory features